ExploRNA Therapeutics develops mRNA-based therapeutic platforms, including novel cap analogs ExploCap® and AvantCap®, to enhance the efficacy of mRNA vaccines and treatments. The company addresses the need for improved delivery and stability of mRNA therapeutics, facilitating better disease prevention and treatment options for pharmaceutical partners.
Funding
$813.6K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The efficacy of mRNA vaccines and therapeutics is often limited by challenges in mRNA delivery, stability, and translation efficiency. Traditional mRNA capping methods can be inefficient, leading to suboptimal therapeutic outcomes and increased development costs.
Solution
ExploRNA Therapeutics develops and manufactures novel cap analogs, including ExploCap® and AvantCap®, designed to enhance the performance of mRNA-based therapies. These cap analogs improve mRNA stability, increase translation efficiency, and reduce immunogenicity, leading to improved therapeutic outcomes. ExploRNA's technology platform provides pharmaceutical partners with advanced tools to optimize mRNA vaccines and treatments for a wide range of diseases. By focusing on innovative capping solutions, ExploRNA aims to overcome the limitations of current mRNA technologies and accelerate the development of more effective and safer mRNA therapeutics.
Target Audience
ExploRNA's primary customers are pharmaceutical and biotechnology companies developing mRNA-based vaccines and therapeutics, as well as research institutions focused on mRNA technology.
Features
- ExploCap®: Delivers high IVT yields and capping efficiencies.
- AvantCap® AG: Provides high yields and capping efficiencies.
- AvantCap® Q1: Delivers high yields and capping efficiencies across a wide range of IVT conditions.
- AvantCap® Q2: Delivers Cap 2 modification with high yields and capping efficiencies across a wide range of IVT conditions.
- Cap analogs are designed to improve mRNA stability and reduce immunogenicity.
- Products available for purchase via online shop.